Effect of ranitidine, a new H2-antagonist, on gastric and pancreatic secretion in duodenal ulcer patients.
The effects of a new H2-receptor blocker, ranitidine, given intravenously (for comparison with cimetidine) or orally an gastric and pancreatic secretion have been studied in duodenal ulcer patients. Ranitidine appears to be several times more potent and a longer-acting inhibitor of gastric secretion than cimetidine. This H2 blocker does not affect pancreatic bicarbonate and enzyme secretion.
D000284:Administration, Oral; D000328:Adult; D002927:Cimetidine / Q000008:administration & dosage / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003864:Depression, Chemical; D004381:Duodenal Ulcer / Q000188:drug therapy / Q000503:physiopathology*; D004386:Duodenum; D005663:Furans / Q000627:therapeutic use*; D005750:Gastric Juice / Q000378:metabolism*; D006635:Histamine H2 Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007275:Injections, Intravenous; D007419:Intestinal Secretions / Q000378:metabolism; D010189:Pancreatic Juice / Q000378:metabolism*; D011899:Ranitidine
D005663:Furans; D006635:Histamine H2 Antagonists; D002927:Cimetidine; D011899:Ranitidine